- Home
- MGIH vs SABS Comparison
MGIH vs SABS Comparison
Compare MGIH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- SABS
- Stock Information
- Founded
- MGIH 1978
- SABS 2014
- Country
- MGIH Hong Kong
- SABS United States
- Employees
- MGIH N/A
- SABS N/A
- Industry
- MGIH Publishing
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- SABS Health Care
- Exchange
- MGIH Nasdaq
- SABS Nasdaq
- Market Cap
- MGIH 18.0M
- SABS 15.8M
- IPO Year
- MGIH 2023
- SABS N/A
- Fundamental
- Price
- MGIH $2.19
- SABS $2.28
- Analyst Decision
- MGIH
- SABS Strong Buy
- Analyst Count
- MGIH 0
- SABS 4
- Target Price
- MGIH N/A
- SABS $9.50
- AVG Volume (30 Days)
- MGIH 934.2K
- SABS 516.5K
- Earning Date
- MGIH 10-29-2025
- SABS 11-05-2025
- Dividend Yield
- MGIH N/A
- SABS N/A
- EPS Growth
- MGIH N/A
- SABS N/A
- EPS
- MGIH N/A
- SABS N/A
- Revenue
- MGIH $28,866,993.00
- SABS $114,698.00
- Revenue This Year
- MGIH N/A
- SABS N/A
- Revenue Next Year
- MGIH N/A
- SABS N/A
- P/E Ratio
- MGIH N/A
- SABS N/A
- Revenue Growth
- MGIH N/A
- SABS N/A
- 52 Week Low
- MGIH $1.34
- SABS $1.00
- 52 Week High
- MGIH $6.83
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- MGIH 47.20
- SABS 51.84
- Support Level
- MGIH $2.21
- SABS $1.85
- Resistance Level
- MGIH $2.48
- SABS $2.60
- Average True Range (ATR)
- MGIH 0.21
- SABS 0.19
- MACD
- MGIH -0.05
- SABS 0.02
- Stochastic Oscillator
- MGIH 14.52
- SABS 57.33
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.